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Metal swap between Zn7metallothionein-3 and amyloid-β-Cu
protects against amyloid-β toxicity
Abstract
Aberrant interactions of copper and zinc ions with the amyloid-β peptide (Aβ) potentiate Alzheimer
disease (AD) by participating in the aggregation process of Aβ and in thegeneration of reactive oxygen
species (ROS). The ROS production and the neurotoxicity of Aβ are associated with copper binding.
Metallothionein-3 (Zn7MT-3), an intra- andextracellularly occurring metalloprotein, is highly expressed
in the brain and down-regulated in AD. This protein protects, by an unknown mechanism, cultured
neurons from the toxicity of Aβ. Herein, we show that a metal swap between Zn7MT-3 and soluble and
aggregated Aβ1-40-Cu(II) abolishes the ROS production and the related cellular toxicity. In this
process, copper is reduced by the protein thiolates forming Cu(I)4Zn4MT-3 in which an air stable
Cu(I)4-thiolate cluster and two disulfide bonds are present. The discovered protective effect of
Zn7MT-3 from the copper-mediated Aβ1-40 toxicity may lead to newtherapeutic strategies in treating
AD.
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Aberrant interactions of copper and zinc ions with the amyloid–β peptide (Aβ) potentiate 
Alzheimer disease (AD) by participating in the aggregation process of Aβ and in the 
generation of reactive oxygen species (ROS). The ROS production and the neurotoxicity of 
Aβ are associated with copper binding. Metallothionein–3 (Zn7MT–3), an intra– and 
extracellularly occurring metalloprotein, is highly expressed in the brain and down–
regulated in AD. This protein protects, by an unknown mechanism, cultured neurons from 
the toxicity of Aβ. Herein, we show that a metal swap between Zn7MT–3 and soluble and 
aggregated Aβ1–40–Cu(II) abolishes the ROS production and the related cellular toxicity. In 
this process, copper is reduced by the protein thiolates forming Cu(I)4Zn4MT–3 in which an 
air stable Cu(I)4–thiolate cluster and two disulfide bonds are present. The discovered 
protective effect of Zn7MT–3 from the copper–mediated Aβ1–40 toxicity may lead to new 
therapeutic strategies in treating AD. 
 
A hallmark of Alzheimer disease (AD) brains is the presence of extracellular β–amyloid plaques 
rich in metals such as Zn, Cu and Fe1. These fibrillar deposits are mainly composed of a 39–43 
residue Aβ peptide, a proteolytic fragment generated from the amyloid precursor protein (APP) 
by β– and γ–secretases1. There is significant evidence indicating that the Aβ peptides can interact 
with metal ions such as Zn(II) and Cu(II), thereby participating in their aggregation and in the 
production of ROS1, 2. Whereas the copper–induced Aβ aggregation is related to the ROS 
production and neurotoxicity3, the zinc–induced Aβ aggregation is considered to be 
neuroprotective4. The ROS are generated by Aβ–Cu(II) through the redox cycling of copper 
which requires its reduction by biological components such as ascorbate (1), glutathione (2), 
dopamine (3), and cholesterol (4)5, 6.  A dysregulation of metal ion homeostasis, as occurs in AD, 
may foster an environment that promotes such degenerative conditions. The modulation of brain 
metal ion homeostasis, the reduction of aberrant metal–protein interactions by MPAC (metal–
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protein attenuating compounds) and the attenuation of oxidative stress have been proposed as 
potential therapeutic interventions in AD 7.  
 Metallothionein–3 (Zn7MT–3), also known as the neuronal growth inhibitory factor 
(GIF), is highly expressed in the normal human brain, where it plays an important role in the 
homeostasis of the essential metal ions Cu(I) and Zn(II) and neuronal outgrowth8, 9. The structural 
studies revealed that Zn7MT–3, like other mammalian metallothioneins, contains two metal–
thiolate clusters localized in independent protein domains, i.e., the Zn3(CysS)9 cluster in the N–
terminal β–domain and the Zn4(CysS)11 cluster in the C–termial α–domain10–12. In the brain, 
Zn7MT–3 is localized in neurons, astrocytes and in the extracellular space in comparable 
amounts13 and was found down–regulated in AD14. Furthermore, Zn7MT–3, by an unknown 
mechanism, rescues the neuronal cells from the toxicity of Aβ1–40 peptide15. As the toxicity of Aβ 
stems from the ROS production by Aβ–Cu(II), we hypothesized that a transmetallation between 
Aβ1–40–Cu(II) and Zn7MT–3 may be the underlying molecular mechanism. The central feature of 
the current study was the spectroscopic characterization of this process and its verification in cell 
culture experiments. We found that a metal swap between Zn7MT–3 and Aβ–Cu(II), 
accompanied by Cu(II) reduction and binding into the protein structure, is the underlying 
mechanism by which the ROS production and related cellular toxicity is quenched. This finding 
signifies a so far unrecognized protective role of this protein in the brain. 
 
RESULTS 
Zn7MT–3 removes copper from soluble Aβ1–40–Cu(II) 
Here, we addressed the intriguing question whether a metal exchange between Zn7MT–3 and 
soluble Aβ1–40–Cu(II) may occur and whether it involves a redox reaction. This study builds on 
our recent work in which, by complementary spectroscopic techniques, we provided evidence that 
Zn7MT–3 through the cooperative formation of an air stable Cu(I)4Zn4MT–3 species efficiently 
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scavenges and redox silences free extracellularly occurring Cu(II)16. In Aβ1–40–Cu(II) copper is 
tightly bound in a square–planar geometry through three histidine ligands (His6, His13, and His14) 
and an ill defined fourth ligand17–19. Zinc contained in both metal–thiolate clusters of Zn7MT–3 is 
bound with a high affinity in a tetrahedral geometry through terminal and µ–bridging thiolate 
ligands. The characteristic metal–induced absorption and circular dichroism (CD) features of 
copper and zinc complexes with histidine ligands in Aβ substantially differ from those with 
cysteine ligands in MT–3, thus permitting the detection of changes in the metal coordination 
environment and oxidation state upon their binding (Fig. 1).  
 The current studies were carried out using Aβ1–40–to–copper binding stoichiometries ≤ 1, 
to ascertain the metal occupancy of the physiologically relevant high–affinity binding site. The 
absorption spectrum of freshly prepared Aβ1–40–Cu(II) is characterized by the HisN–Cu(II) 
charge–transfer bands and the Cu(II) d–d bands centered around 230 and 600 nm, respectively18–
20
 (Supplementary Fig. 1 online). The corresponding EPR spectrum of Aβ1–40–Cu(II) at pH 7.4 
originates from a mixture of at least two Aβ1–40–Cu(II) complexes. The predominant species 
shows an axial signal typical of type 2 copper with the AII, gII and g⊥ values of 170 G, 2.26 and 
2.06, respectively (Fig. 1d). These features are typical of Cu(II) coordination by three nitrogen 
and one oxygen ligands (3N1O)18, 19. Since MT–3 is devoid of aromatic amino acids, the metal–
induced shoulder in the absorption spectrum of Zn7MT–3 at about 235 nm originates from the 
CysS–Zn(II) charge–transfer transitions11. Addition of Zn7MT–3 to Aβ1–40–Cu(II) revealed new 
absorption features above 250 nm characteristic of the CysS–Cu(I) charge–transfer transitions21. 
These results and the absence of the EPR signal of Aβ1–40–Cu(II) indicated that the Cu(II) 
removal from Aβ1–40–Cu(II), reduction to Cu(I) and binding to MT–3 occurred (Fig. 1a). The 
observed intensity decrease of the CysS–Zn(II) charge–transfer envelope in the high energy 
region was in agreement with Zn(II) release from Zn7MT–3 during this process. 
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 The corresponding CD studies better documented this reaction (Fig. 1b). Zn7MT–3 
shows a biphasic CD profile with strong CD bands at (+)247 and (–)228 nm, and a crossover 
point at 239 nm. These CD features originate from an excitonic splitting of the first CysS–Zn(II) 
charge transfer transition at 235 nm11. By marked contrast, the CD spectrum of Aβ1–40–Cu(II) 
shows only a small contribution to that of Aβ1–40 in the spectral region between 230–260 nm. 
Addition of Aβ1–40–Cu(II) to Zn7MT–3 resulted in new intense dichroic bands mainly in the low 
energy region of the spectrum (above 240 nm) (Fig. 1b). The newly developed CysS–Cu(I) 
charge transfer CD bands at about (+)255 and (–)285 nm were identical in the size and the 
position to those already observed in the reaction of Zn7MT–3 with free Cu(II)16 (Supplementary 
Fig. 2 online). These results and the mass of the isolated protein of 7,431.0 Da, obtained by 
electrospray ionization time–of–flight mass spectrometry (ESI–TOF MS) (Supplementary Table 
1 online), suggested that also in this case Cu(I)4Zn4MT–3 containing two disulfide bonds was 
formed. Evidence for the presence of a Cu(I)4–thiolate cluster in Cu(I)4Zn4MT–3 was provided by 
the appearance of its characteristic low temperature Cu(I) emission spectrum16 (Fig. 1c). This 
luminescence spectrum is characterized by high– and low–energy emissive bands centered at 425 
and 560 nm with lifetimes of 36 and 130 µs, respectively, consistent with their origin from two 
triplet–excited state manifolds. The presence of two emissive bands in Cu(I)4 clusters has been 
correlated with short internuclear Cu···Cu distances (< 2.8 Å, allowing a d10–d10 orbital overlap). 
Accordingly, the high energy emissive band in Cu(I)4Zn4MT–3 has been assigned to 3CC (cluster 
centered) origin and that at low energy to triplet charge transfer6, 16. Consequently, peculiar 
metal–metal interactions in this cluster exist.  
 
Zn7MT–3 removes copper from aggregated Aβ1–40–Cu(II) 
In the absence of transition metals, Aβ1–40,42 can undergo a slow time–dependent aggregation 
giving rise, at the late stages, to a parallel β–sheet structure typical of amyloid fibrillar deposits22. 
However, Cu(II) binding to soluble Aβ1–40,42 promotes their rapid aggregation into amorphous not 
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yet fully elucidated structures and fibrillar forms2, 23–25. In both, the soluble and insoluble Aβ1–
40,42–Cu(II) identical metal coordination environments exist26. We investigated the possibility 
whether Zn7MT–3 could also remove copper from the insoluble Aβ1–40–Cu(II) aggregates, where 
it may be buried and not accessible. The generated sodium dodecyl sulfate (SDS)–resistant Aβ1–
40–Cu(II) pellet was isolated by centrifugation and incubated with an equimolar concentration of 
Zn7MT–3. Atomic absorption spectroscopy of soluble and insoluble fractions showed that the 
incubation with Zn7MT–3 completely removed copper from the Aβ1–40–Cu(II) aggregates and that 
a corresponding amount of Zn(II) was bound to precipitated Aβ1–40 instead (Fig. 2a). The 
presence of characteristic luminescence features of the Cu(I)4–thiolate cluster in the soluble 
fraction provided evidence for a metal swap between Zn7MT–3 and insoluble Aβ1–40–Cu(II) 
aggregates (Fig. 2b). Next we sought to demonstrate the metal swap also with soluble Aβ–Cu(II) 
complexes. We used the model peptide Aβ1–28 in complex with Cu(II) (Aβ1–28–to–Cu(II) ratio 
1:1), because it remains soluble and monomeric with time27 and is thus better suited for ESI–MS 
analyses. The obtained mass peaks of Cu(I)4Zn4MT–3, Aβ1–28–Zn(II), and free Aβ1–28, due to the 
low Kd of soluble Aβ–Zn(II) (µM range)28 confirmed the metal swap (Supplementary Fig. 3 and 
Supplementary Table 1 and 2 online).  
 
Metal swap abolishes the ROS production 
The soluble oligomeric aggregates of Aβ are substantially more toxic than fibrils or naturally 
occurring monomers29. Since the soluble Aβ–Cu(II) generates substantial amounts of ROS, they 
represent the dominant species responsible for the Aβ–Cu(II) toxicity3, 6, 30. Furthermore, both the 
ROS production and copper induced aggregation are responsible for the formation of SDS–
resistant Aβ1–40–Cu(II) oligomers31. In the recent work, the pathway of Aβ aggregation with 
Cu(II) in comparison with sole Aβ was investigated32. The studies show that the formation of Aβ–
Cu(II) aggregates proceeds through a different pathway involving the formation of small soluble 
species whose nature differ from that formed with Aβ. Although not studied, the nature of soluble 
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species formed with Zn(II) must also differ as Aβ1–40–Zn(II) aggregates are soluble in SDS2, 33.  
To examine the effect of Zn7MT–3 on the nature of Aβ1–40–Cu(II) precipitates formed, we 
analyzed by reducing SDS–PAGE the amounts of monomeric Aβ1–40 which can be solubilised by 
SDS (Fig. 3a). The Cu(II) induced insoluble Aβ1−40 aggregates prepared after 72 h incubation 
showed only a low content of SDS–soluble monomers, as revealed by a strong band with an 
apparent molecular mass of Aβ1−40 between 4–5 kDa. However, the co–incubation of the 
insoluble Aβ1–40–Cu(II) aggregates for 72 h with increasing concentrations of Zn7MT–3 led to 
increasing amounts of SDS–soluble monomeric Aβ1−40. Consequently, the metal swap did not 
impede Aβ1–40 aggregation, as it is also promoted by Zn(II), but rather the nature of the final 
product. 
The oxidative stress represents a downstream effect of abnormal Aβ–Cu(II) interactions 
in AD and the Aβ–Zn(II) formation is potentially neuroprotective4, 34. In air, ROS such as H2O2, 
O2• – and highly reactive OH• radicals are generated by Aβ–Cu(II) via a series of reactions, 
including a Fenton or a Haber–Weiss reaction, causing an oxidative modification of DNA, lipids, 
and proteins, a characteristic hallmark of Aβ–Cu(II) toxicity35. The redox cycling of Cu(II) bound 
to Aβ is catalyzed by cellular reductants. Here, we investigated the effect of Zn7MT–3 on the 
ascorbate–induced hydroxyl radical production from the soluble and insoluble Aβ1–40–Cu(II) 
aggregates by fluorescence spectroscopy using the hydroxyl radical scavenging compound 3–
coumarin carboxylic acid (3–CCA, 5). The ascorbate concentration used (300 µM) was similar to 
that reported to be present in the cerebrospinal fluid and in the extracellular space of the brain36. 
The observed hydroxyl radical production from soluble Aβ–Cu(II) was characterized by an 
almost linear increase of the fluorescence signal of the product 7–hydroxo–3–coumarin 
carboxylic acid (7–OH–CCA, 6) with time (Fig. 3b). However, the same experiments performed 
in the presence of Zn7MT–3 resulted in a complete quenching of the hydroxyl radical production. 
A similar quenching effect of Zn7MT–3 was also seen with insoluble Aβ1–40–Cu(II) aggregates 
(Fig. 3c). The results showed that only in the presence of Zn7MT–3 the OH• production was 
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completely quenched signifying the metal swap and the stability of the generated Cu(I)4Zn4MT–3 
species.  
 
Zn7MT–3 protects cells against Aβ1–40 toxicity 
To ascertain whether the metal swap between Aβ1–40–Cu(II) and Zn7MT–3 is the likely 
mechanism for the reported protective effect of Zn7MT–3 from Aβ1–40–Cu(II) toxicity15, we 
performed cell viability experiments using the human SH–SY5Y neuroblastoma cell line (Fig. 4). 
We measured cell viability using the fluorescence dye 5–carboxyfluorescein diacetate, 
acetoxymethyl ester (5–CFDA, AM; 7) added to the medium. The results obtained in the absence 
of Zn7MT–3 revealed the reported Aβ1–40–Cu(II) toxicity (Fig. 4a). However, this toxic effect 
could be markedly reduced by the addition of Zn7MT–3, but not by the fully Cu(I) loaded 
Cu(I)8MT–3 form which is unable to bind any additional copper. Furthermore, the EPR and 
luminescence measurements carried out on cell culture samples illustrated the Cu(II) reduction 
and the formation of Cu(I)4Zn4MT–3 (Fig. 4c,d). Next, we sought to demonstrate that the 
observed cellular toxicity originates from the ROS production caused by redox cycling of copper 
in the presence of ascorbate. Therefore, we compared the cell viability assay in the presence of 
Aβ1–40–Cu(II), Aβ1–40 and free Cu(II) with that of the control in which increasing concentrations 
of H2O2 were used as the source of ROS in the cell culture medium (Supplementary Fig. 4 
online). Since the fluorescence dye 5–CFDA, AM was sensitive to H2O2, we determined the cell 
viability in the presence of H2O2 through the reduction of 3–(4,5–dimethylthiazol–2–yl)–2,5–
diphenyltetrazolium bromide (MTT, 8). The results revealed that the cellular toxicity is in line 
with the ROS generated by redox cycling of Cu(II) in the presence of ascorbate.   
 The cell viability experiments clearly demonstrated that Zn7MT–3 protects cells from 
copper–mediated toxicity. However, a comparison of the EPR g–values and hyperfine splitting of 
Aβ1–40–Cu(II) in the buffer solution (Fig. 1d) with those obtained in cell culture experiments (Fig. 
4c) showed differences suggestive of the formation of other Cu(II) complexes. To assess their 
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presence, we separated the high and low molecular components of the cell culture medium to 
which Aβ1–40–Cu(II) was added by ultrafiltration using 3 and 30 kDa cut–off membranes. The 
results showed that under the experimental conditions of the cell culture studies a significant part 
of Cu(II), originally bound to Aβ1–40–Cu(II), was redistributed among high ( > 30 kDa) and low 
molecular weight ( < 3 kDa) components of the medium. To demonstrate the toxic nature of Aβ1–
40–Cu(II) in cell culture, we carried out cell viability experiments using diluted Dulbecco's 
Modified Eagle's Medium (DMEM) in which fetal calf serum (FCS) was absent (Fig. 4b). Under 
these conditions, both the EPR and ultrafiltration experiments using 3 kDa membrane revealed 
the predominant presence of the Aβ1–40–Cu(II) complex (~ 70%) (Supplementary Figs. 5 and 6, 
online). The cellular toxicity of Aβ1–40–Cu(II) (Fig. 4b) was comparable to that observed with the 
fully supplemented medium (Fig. 4a). This suggests that Aβ1–40–Cu(II) itself represents a major 
redox active species responsible for cellular toxicity. The characteristic luminescence fingerprint 
of Cu(I)4Zn4MT–3, obtained upon the addition of Zn7MT–3 to the cell culture medium containing 
Aβ1–40–Cu(II), confirmed the metal swap (Supplementary Fig. 7, online). Furthermore, a 
comparison of cellular toxicity of free Cu(II) in the presence and absence of ascorbate revealed a 
markedly increased toxicity in the former case, confirming that the ROS production is responsible 
for this effect. Thus, a metal swap between Zn7MT–3 and Aβ1–40–Cu(II) together with copper 
removal from other complexes may efficiently protect cells from copper–mediated toxicity. 
 
Discussion  
 
The studies presented herein highlight the important protective role of Zn7MT–3 against copper–
mediated toxicity of Aβ1–40–Cu(II). The origin of this effect stems from the different chemistry 
and metal affinities of Aβ1–40 compared to MT–3. Aβ1–40 possesses a high–affinity binding site for 
Cu(II) and Zn(II) with apparent stability constants reported in the range between 10–6 – 10–11 M 
and 10–4 – 10–7 M, respectively 18, 19, 37, 38. An average apparent stability constant for Zn(II) in 
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Zn7MT–3 is 1.6 × 10–11 M 39. As the formation of stable Cu(II) thiolates complexes is to a large 
extent impeded by the intrinsic tendency of the coordinated thiolates to promote reduction of 
Cu(II) concomitant with their oxidation to disulfides, a transmetallation through Cu(II) 
displacement and Zn(II) binding to Aβ1–40 cannot take place. Although the stability constants for 
Cu(I) in complex with Aβ1–40 and MT–3 are not known, by analogy with other mammalian MTs 
the latter can be estimated to be ~ 10–19 M40. This and the preference of soft thiolate ligands for 
soft Cu(I) suggests that Cu(I) binding to MT–3 would be preferred. The documented high 
nucleophilicity of thiolate ligands in Zn7MT–3 and the ability of the MT–3 structure to 
accommodate widely different coordination geometries such as those for Cu(I) (digonal, trigonal) 
and Zn(II) (tetrahedral) in its metal–thiolate clusters afford the bases for such a reaction.  
 We showed by a range of complementary spectroscopic, biochemical and cell biological 
techniques that the thiolate/disulfide couple in Zn7MT–3 represents an efficient system linking 
zinc–thiolate cluster reactivity to Cu(II) reduction and removal from Aβ1–40–Cu(II), generating 
oxygen stable Cu(I)4Zn4MT–3 and redox inert Aβ1–40–Zn(II). In this process two disulfide bonds 
are formed in the Cu(I)4Zn4MT–3 structure, in agreement with the reduction of four Cu(II), 
concomitant with the release of three Zn(II) ions 16. Previously, by immunochemical methods, we 
could show that the Cu(I)4–thiolate cluster is located in the β–domain of Cu(I)4Zn4MT–3 16. As 
the α–domain still contains four Zn(II) ions, we inferred that the two disulfide bonds ought to be 
present in the β–domain. The presence of two disulfides in the β–domain, leaving five reduced 
thiolate ligands, would be sufficient to coordinate four Cu(I) ions through terminal and bridging 
sulfurs in digonal and/or trigonal coordination. However, a direct involvement of disulfide 
sulfur(s) in Cu(I) coordination cannot be excluded, as in inorganic model complexes a Cu(I) 
coordination by a disulfide bridge sulfur has been seen41, 42. Nevertheless, the stability of the 
Cu(I)4–thiolate cluster in air oxygen is striking and not understood. We reasoned that the 
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structural constraints and the short Cu(I)···Cu(I) distances (< 2.8Å) in the Cu(I)4–thiolate cluster, 
leading to peculiar metal–metal interactions, may be important for its stability 16.  
Previous studies showed that metals modulate Aβ toxicity in neuronal cultures, with 
Cu(II) ions increasing Aβ toxicity whilst Zn(II) ions attenuate it 4, 34. Our cell viability assay in 
the presence of Zn7MT–3 showed a marked reduction of Aβ1–40–Cu(II) toxicity. This together 
with the absence of the EPR signal of Aβ1–40–Cu(II) and the appearance of the characteristic 
luminescence spectrum of Cu(I)4Zn4MT–3 strongly suggest that a metal swap mechanism is 
responsible for the protective effect of the protein against Aβ1–40 toxicity15. However, the results 
of cell culture studies revealed that a metal swap in vivo does not occur exclusively with Aβ1–40–
Cu(II), as the degree of copper binding to Aβ  depends on the concentration of competing ligands. 
As a result, besides Aβ1–40–Cu(II), other redox active Cu(II) complexes may also potentiate the 
ROS production. Our studies imply that Zn7MT–3 is capable to target also these Cu(II) 
complexes.  
The Aβ–Cu(II) toxicity is linked to the ROS production mainly from the soluble 
aggregated form43. However, in very recent studies a significant neurotoxicity of aged Aβ1–42–
Cu(II) was also observed for Cu(II) : peptide molar ratio of 1:1, but not if sub– or supra–
equimolar ratios were used32. This indicates that both early aggregated forms and aged aggregates 
at an equimolar ratio are neurotoxic. In the current studies, equimolar ratios were used in the 
generation of soluble and aged Aβ1–40–Cu(II) aggregates. The ROS generation through redox 
cycling of Cu(II) bound to Aβ requires its reduction during this process. This is catalyzed by 
cellular reductants like cholesterol, neurotransmitters (dopamine and L–DOPA (9)), and 
antioxidants such as ascorbate5, 6. Ascorbate is actively transported into the CNS reaching a 
concentration of 200–400 µM in the brain extracellular fluid and of ~ 10 mM in neurons 36. The 
ability of Zn7MT–3 to quench ascorbate–induced hydroxyl radical production by soluble and 
insoluble Aβ1–40–Cu(II) aggregates accentuates the protective role of Zn7MT–3 and the stability 
of the generated Cu(I)4Zn4MT–3 species. The absence of hydroxyl radical production by copper 
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contained in the Cu(I)4Zn4MT–3 structure presumably results either from the unfeasible 
formation of the complex between the Cu(I)4–thiolate cluster and oxygen or from the increased 
redox potential of the Cu(I)4–thiolate cluster preventing the oxygen reduction. The observation 
that the products of the metal swap reaction Aβ1–40–Zn(II) and Cu(I)4Zn4MT–3 occurred not only 
with soluble, but also with the SDS–resistant Aβ1–40–Cu(II) precipitates underscores the similarity 
of this process.  
 A dual role as a pro– and antioxidant in copper redox cycling in a Fenton–type reaction 
has been proposed for Aβ 44, 45. The antioxidative activity of Aβ is mainly mediated by chelating 
transition metal ions, keeping concentrations of redox–active metals at low levels, rather than by 
free radical scavenging by Met35 of the peptide 46. This effect is exemplified by the differences in 
hydroxyl radical production between free Cu(II) and that bound to Aβ1–40 (Fig. 3b). Although 
high Aβ concentrations substantially reduce free Cu(II) toxicity, this effect just delays the ROS 
related brain injury caused by Aβ–Cu(II). In addition, copper in Aβ1–40–Cu(II) can be reduced to 
Cu(I) by Met35, leading to its oxidation. In view of our data, we suggest that in all these 
situations Zn7MT–3 would efficiently scavenge both Cu(II) and Cu(I). Overall, the demonstrated 
reduction of Cu(II) contained in Aβ1–40–Cu(II) and its concomitant binding into the N–terminal 
domain of Cu(I)4Zn4MT–3 results in a “redox silent” Cu(I)4–thiolate cluster which is stable 
toward ascorbate–induced copper–catalyzed redox cycling thus preventing the ROS production 
from molecular oxygen. Thus, Zn7MT–3 may play an important protective role in a number of 
pathological situations where dysregulation of copper homeostasis exist.  
 
 
METHODS  
Materials. Human amyloid–β peptides (Aβ1−28, Aβ1−40) were obtained by standard Fmoc peptide 
chemical synthesis or purchased from common commercial sources. Recombinant human MT–3 
was expressed in E. coli strain BL21(DE3)pLys, purified, and reconstituted with Zn(II) as 
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described11. The correctness of the peptide synthesis and the protein expression was verified by 
ESI–MS (Supplementary Figs. 8–10 online).  
 
Electronic absorption and circular dichroism measurements. The stock solutions of Aβ1–40 
were prepared as described47 and their concentrations determined by tyrosine absorbance (ε276 = 
1,410 M–1cm–1). The Aβ1–40–Cu(II) complexes (peptide/metal ratio 1:1) were obtained by mixing 
freshly prepared solutions of Aβ1–40 (25 µM) with 1 mol equivalent of CuCl2 in 20 mM Tris–HCl, 
100 mM NaCl, pH 7.4. The interaction between Aβ1–40–Cu(II) and Zn7MT–3 was investigated by 
mixing 25 µM Aβ1–40–Cu(II) with the concentrated solution of Zn7MT–3 (peptide/protein ratio 
1:0.2) Absorption and circular dichroism (Jasco, J–810) measurements were performed in 20 mM 
Tris–HCl, 100 mM, NaCl, pH 7.4. 
 
Cu(I) luminescence measurements at 77 K. Low temperature Cu(I) luminescence spectra and 
emission decay lifetimes were obtained using a SPEX fluorolog spectrofluorimeter equipped with 
a 1934C phosphorimeter accessory employing a 22.5° detection geometry. Samples were 
prepared as described for circular dichroism measurements. Measurements of the emission 
spectra (λexc = 300 nm) were carried out at 77 K on microcrystalline frozen samples using a 55–µs 
delay and a 300–µs sample window. Lifetime measurements were performed on the same 
samples using 10–µs and 15–µs acquisition delay increments, 300 and 800 µs acquisition 
windows for emissive bands at 425 nm and 565 nm, respectively. The luminescence bands 
decayed according to a single exponential function.  
 
EPR measurements. X–band EPR spectra were recorded on an Elexsys ESP 500 spectrometer 
(Bruker Inc.) operating at a microwave frequency of ~ 9.5 GHz. The spectra were recorded at 100 
K employing a nitrogen gas flow using a microwave power of 20 mW and modulation amplitude 
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of 10 Gauss. Prior to measurements, the samples were mixed with glycerol (20% v/v) to obtain 
homogeneous freezing.  
 
Metal swap between insoluble aggregated Aβ1–40–Cu(II) and Zn7MT–3. The precipitated Aβ1–
40–Cu(II) aggregates were generated by incubation of 1 ml of Aβ1–40–Cu(II) (25 µM, 
peptide/metal ratio 1:1) in 20 mM Tris–HCl, 100 mM NaCl, pH 7.4, for 48 at 37 °C in sealed 
tubes under continuous stirring (300 rpm). Precipitated Aβ1–40–Cu(II) was isolated by 
centrifugation (21,000 × g, 1 h, at 4 °C). To this sample 1 ml of Zn7MT–3 (25 µM) was added 
and the mixture incubated for 1 h at 37 °C under continuous stirring. In the next centrifugation 
step the peptide pellet and the supernatant were separated, diluted into 15 mM HNO3, vigorously 
vortexed, and sonicated in a water bath. The copper and zinc content in both fractions was 
determined by flame atomic absorption spectroscopy (SpectraAA–110, Varian Inc.). 
Independently, a low temperature Cu(I) luminescence emission spectrum and emission decay 
lifetimes of the supernatant were recorded as described above.  
 
SDS–PAGE characterization of the nature of Aβ1−40–Cu(II) aggregates. The SDS–resistant 
Aβ1−40 –Cu(II) aggregates were generated by mixing of 100 µl freshly diluted aliquots of Aβ1–40 
(25 µM) in 20 mM Tris–HCl, 100 mM NaCl, pH 7.4, with 1 mol equivalent of CuCl2 (in H2O). 
The Aβ1−40 –Cu(II) complex was mixed with Zn7MT–3 (200 µM) to a final protein concentration 
between 50 nM and 25 µM and incubated for 72 h at 37 °C under continuous stirring (300 rpm) in 
sealed tubes in the presence of 300 µM ascorbate. After incubation, the metal containing pellets 
of Aβ1−40 were separated from the supernatant by centrifugation (21,000 × g, 1 h, at 4°C). The 
obtained pellet was re–suspended in 10 µl of the loading buffer (10 mM Tris–HCl, 10 mM 
EDTA, 20% (v/v) glycerol, 1% (w/v) SDS, 0.025% (w/v), bromophenol blue, 100 mM DTT, 0.7 
M 2–mercaptoethanol, pH 7.5), heated for 5 minutes at 95 °C, and cooled down to room 
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temperature. Amounts of SDS soluble monomeric Aβ1−40 were analyzed by SDS–PAGE using 4–
20% Tris–HCl gradient gels stained with Coomassie Brillant Blue. In parallel, similar 
experiments in the absence of Zn7MT–3 were also carried out.  
 
Measurements of copper–catalyzed hydroxyl radical production. The ascorbate–driven 
copper–catalyzed hydroxyl radical production was monitored by fluorescence spectroscopy using 
the hydroxyl radical scavenging compound 3–CCA (Sigma–Aldrich). The formation of the 
product 7–OH–CCA was followed by fluorescence spectroscopy (excitation at 395 nm; emission 
at 450 nm; SPEX fluorolog) over 120 min48. The hydroxyl radical production was measured upon 
the addition of ascorbate (300 µM) to the samples containing (i) CuCl2 (1 µM), (ii) Aβ1–40–Cu(II) 
generated upon the reaction of Aβ1–40 (4 µM) with CuCl2 (1 µM), and (iii) Aβ1–40–Cu(II) to which 
1 µM Zn7MT–3 was added. As a control, the hydroxyl radical production upon the reaction of 
CuCl2 (1 µM) with 1 mol equivalent of Zn7MT–3 was also measured. All measurements were 
carried out in 20 mM phosphate buffer, pH 7.4, containing 100 µM 3–CCA. For the 
determination of hydroxyl radical production by insoluble Aβ1−40–Cu(II) aggregates, Aβ1−40–
Cu(II) (25 µM) was incubated for 96 h at 37°C in 20 mM Tris–HCl, 100 mM NaCl, pH 7.4, under 
continuous agitation. The Aβ1−40–Cu(II) precipitates were isolated by centrifugation (21,000 × g, 
1 h, 4 °C) and washed with 20 mM phosphate buffer pH 7.4. The precipitates were re–suspended 
into the same buffer in the presence or absence of 1 mol equivalent of Zn7MT–3.  
 
Cu(II) EPR and low temperature Cu(I) luminescence measurements of cell cultures. The 
Cu(II) EPR and low temperature Cu(I) luminescence measurements were performed on cell 
culture samples used in the cell survival assays.  
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Cell viability assay. Human neuroblastoma SH–SY5Y cell viability was measured in 24–well 
plates by using either the fluorescence dye 5–CFDA, AM (Molecular Probes) or MTT (Sigma–
Aldrich) (Supplementary Methods online). 
 
 
References 
 
1. Adlard, P.A. & Bush, A.I. Metals and Alzheimer's disease. J. Alzheimers Dis. 10, 145–
163 (2006). 
2. Bush, A.I. et al. Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science 
265, 1464–1467 (1994). 
3. Huang, X. et al. Cu(II) potentiation of alzheimer Aβ neurotoxicity. Correlation with cell–
free hydrogen peroxide production and metal reduction. J. Biol. Chem. 274, 37111–
37116. (1999). 
4. Cuajungco, M.P. et al. Evidence that the β–amyloid plaques of Alzheimer's disease 
represent the redox–silencing and entombment of Aβ by zinc. J. Biol. Chem. 275, 19439–
19442 (2000). 
5. Dikalov, S.I., Vitek, M.P. & Mason, R.P. Cupric–amyloid β peptide complex stimulates 
oxidation of ascorbate and generation of hydroxyl radical. Free Radic. Biol. Med. 36, 
340–347 (2004). 
6. Opazo, C. et al. Metalloenzyme–like activity of Alzheimer's disease β–amyloid. Cu– 
dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents 
to neurotoxic H2O2. J. Biol. Chem. 277, 40302–40308. (2002). 
7. Doraiswamy, P.M. & Finefrock, A.E. Metals in our minds: therapeutic implications for 
neurodegenerative disorders. Lancet Neurol. 3, 431–434 (2004). 
8. Vašák, M. & Hasler, D.W. Metallothioneins: new functional and structural insights. Curr. 
Opin. Chem. Biol. 4, 177–183 (2000). 
 17 
9. Uchida, Y., Takio, K., Titani, K., Ihara, Y. & Tomonaga, M. The growth inhibitory factor 
that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein–like 
protein. Neuron 7, 337–347 (1991). 
10. Öz, G., Zangger, K. & Armitage, I.M. Three–dimensional structure and dynamics of a 
brain specific growth inhibitory factor: Metallothionein–3. Biochemistry 40, 11433–
11441 (2001). 
11. Faller, P. et al. Evidence for a dynamic structure of human neuronal growth inhibitory 
factor and for major rearrangements of its metal–thiolate clusters. Biochemistry 38, 
10158–10167 (1999). 
12. Wang, H. et al. Solution structure and dynamics of human metallothionein–3 (MT–3). 
FEBS Lett. 580, 795–800 (2006). 
13. Uchida, Y., Gomi, F., Masumizu, T. & Miura, Y. Growth inhibitory factor prevents 
neurite extension and death of cortical neurons caused by high oxygen exposure through 
hydroxyl radical scavenging. J. Biol. Chem. 277, 32353–32359 (2002). 
14. Yu, W.H., Lukiw, W.J., Bergeron, C., Niznik, H.B. & Fraser, P.E. Metallothionein III is 
reduced in Alzheimer's disease. Brain Res. 894, 37–45 (2001). 
15. Irie, Y. & Keung, W.M. Metallothionein–III antagonizes the neurotoxic and neurotrophic 
effects of amyloid β peptides. Biochem. Biophys. Res. Commun. 282, 416–420 (2001). 
16. Meloni, G., Faller, P. & Vašák, M. Redox silencing of copper in metal–linked 
neurodegenerative disorders: reaction of Zn7metallothionein–3 with Cu2+ ions. J. Biol. 
Chem. 282, 16068–16078 (2007). 
17. Hou, L. & Zagorski, M.G. NMR reveals anomalous copper(II) binding to the amyloid Aβ 
peptide of Alzheimer's disease. J. Am. Chem. Soc. 128, 9260–9261 (2006). 
18. Syme, C.D., Nadal, R.C., Rigby, S.E. & Viles, J.H. Copper binding to the amyloid–beta 
(Aβ) peptide associated with Alzheimer's disease: folding, coordination geometry, pH 
 18 
dependence, stoichiometry, and affinity of Aβ–(1–28): insights from a range of 
complementary spectroscopic techniques. J. Biol. Chem. 279, 18169–18177 (2004). 
19. Guilloreau, L. et al. Structural and thermodynamical properties of CuII amyloid–
beta16/28 complexes associated with Alzheimer's disease. J. Biol. Inorg. Chem. 11, 
1024–1038 (2006). 
20. Fawcett, T.G., Bernarducci, E.E., Kroghjespersen, K. & Schugar, H.J. Charge–transfer 
absorptions of Cu(II)–imidazole and Cu(II)–imidazolate chromophores. J. Am. Chem. 
Soc. 102, 2598–2604 (1980). 
21. Pountney, D.L., Schauwecker, I., Zarn, J. & Vašák, M. Formation of mammalian Cu8–
metallothionein in vitro: evidence for the existence of two Cu(I)4–thiolate clusters. 
Biochemistry 33, 9699–9705 (1994). 
22. Tycko, R. Molecular structure of amyloid fibrils: insights from solid–state NMR. Q. Rev. 
Biophys. 39, 1–55 (2006). 
23. House, E. et al. Aluminium, iron, zinc and copper influence the in vitro formation of 
amyloid fibrils of Aβ42 in a manner which may have consequences for metal chelation 
therapy in Alzheimer's disease. J. Alzheimers Dis. 6, 291–301 (2004). 
24. Karr, J.W., Kaupp, L.J. & Szalai, V.A. Amyloid–beta binds Cu2+ in a mononuclear metal 
ion binding site. J. Am. Chem. Soc. 126, 13534–13538 (2004). 
25. Atwood, C.S. et al. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by 
conditions representing physiological acidosis. J. Biol. Chem. 273, 12817–12826 (1998). 
26. Dong, J. et al. Metal Binding and Oxidation of Amyloid–β within Isolated Senile Plaque 
Cores: Raman Microscopic Evidence. Biochemistry 42, 2768–2773 (2003). 
27. Talmard, C., Guilloreau, L., Coppel, Y., Mazarguil, H. & Faller, P. Amyloid–beta peptide 
forms monomeric complexes with CuIIand ZnII prior to aggregation. ChemBioChem 8, 
163–165 (2007). 
 19 
28. Mekmouche, Y. et al. Characterization of the ZnII Binding to the Peptide Amyloid–β1–16 
linked to Alzheimer's Disease. ChemBioChem 6, 1663–1671 (2005). 
29. Hardy, J. & Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and 
problems on the road to therapeutics. Science 297, 353–356 (2002). 
30. Smith, D.P. et al. Copper–mediated amyloid–β toxicity is associated with an 
intermolecular histidine bridge. J. Biol. Chem. 281, 15145–15154 (2006). 
31. Atwood, C.S. et al. Copper mediates dityrosine cross–linking of Alzheimer's amyloid–
beta. Biochemistry 43, 560–568 (2004). 
32. Smith, D.P. et al. Concentration dependent Cu2+ induced aggregation and dityrosine 
formation of the Alzheimer's disease amyloid–beta peptide. Biochemistry 46, 2881–2891 
(2007). 
33. Bush, A.I., Moir, R.D., Rosenkranz, K.M. & Tanzi, R.E. Science 268, 1921–1923 (1995). 
34. Cardoso, S.M., Rego, A.C., Pereira, C. & Oliveira, C.R. Protective effect of zinc on 
amyloid–β 25–35 and 1–40 mediated toxicity. Neurotox. Res. 7, 273–281 (2005). 
35. Butterfield, D.A., Drake, J., Pocernich, C. & Castegna, A. Evidence of oxidative damage 
in Alzheimer's disease brain: central role for amyloid β–peptide. Trends Mol. Med. 7, 
548–554 (2001). 
36. Rice, M.E. Ascorbate regulation and its neuroprotective role in the brain. Trends 
Neurosc. 23, 209–216 (2000). 
37. Bush, A.I., Pettingell, W.H., Jr., Paradis, M.D. & Tanzi, R.E. Modulation of Aβ 
adhesiveness and secretase site cleavage by zinc. J. Biol. Chem. 269, 12152–12158 
(1994). 
38. Atwood, C.S. et al. Characterization of copper interactions with alzheimer amyloid β 
peptides: identification of an attomolar–affinity copper binding site on amyloid β 1–42. J. 
Neurochem. 75, 1219–1233 (2000). 
 20 
39. Hasler, D.W., Jensen, L.T., Zerbe, O., Winge, D.R. & Vašák, M. Effect of the two 
conserved prolines of human growth inhibitory factor (metallothionein–3) on its 
biological activity and structure fluctuation: comparison with a mutant protein. 
Biochemistry 39, 14567–14575 (2000). 
40. Hamer, D.H. Metallothionein. Annu. Rev. Biochem. 55, 913–951 (1986). 
41. Belle, C., Rammal, W. & Pierre, J.L. Sulfur ligation in copper enzymes and models. J. 
Inorg. Biochem. 99, 1929–1936 (2005). 
42. Ohta, T. et al. Synthesis, structure, and H2O2–dependent catalytic functions of disulfide–
bridged dicopper(I) and related thioether–copper(I) and thioether–copper(II) complexes. 
Inorg. Chem. 39, 4358–4369 (2000). 
43. Smith, D.G., Cappai, R. & Barnham, K.J. The redox chemistry of the Alzheimer's disease 
amyloid β peptide. Biochim. Biophys. Acta 1768, 1976–1990 (2007). 
44. Yoshiike, Y. et al. New insights on how metals disrupt amyloid β–aggregation and their 
effects on amyloid–β  cytotoxicity. J. Biol. Chem. 276, 32293–32299 (2001). 
45. Zou, K., Gong, J.S., Yanagisawa, K. & Michikawa, M. A novel function of monomeric 
amyloid β–protein serving as an antioxidant molecule against metal–induced oxidative 
damage. J. Neurosci. 22, 4833–4841 (2002). 
46. Kontush, A. Amyloid–β: an antioxidant that becomes a pro–oxidant and critically 
contributes to Alzheimer's disease. Free Radic. Biol. Med. 31, 1120–1131 (2001). 
47. Hou, L. et al. Solution NMR studies of the Aβ(1–40) and Aβ(1–42) peptides establish 
that the Met35 oxidation state affects the mechanism of amyloid formation. J. Am. Chem. 
Soc. 126, 1992–2005 (2004). 
48. Manevich, Y., Held, K.D. & Biaglow, J.E. Coumarin–3–carboxylic acid as a detector for 
hydroxyl radicals generated chemically and by gamma radiation. Radiat. Res. 148, 580–
591 (1997). 
 
 21 
ACKNOWLEGEMENTS 
This work was supported by “Action–Concertée–Integrée INTERFACE Physique–Chimie–
Biologie” (P.F), Swiss National Science Foundation Grant 3100A0–100246/1 (M.V.), 
“Programme d’Actions Intégrées Germaine de Staël” Grants 08345VK (M.V. and P.F.), and the 
Hartmann Müller–Stiftung (M.V.). We would like to thank A. Mari and L. Rechignat (LCC, 
Toulouse, France) for EPR measurements, D. Lavabre for preliminary luminescence experiments 
and E. Bellard and M. Fix for help in cell viability experiments (IPBS, Toulouse, France). We 
also thank S. Chesnov (Functional Genomic Center, Zürich, Switzerland) for recording nano–
ESI–MS spectra. 
 
COMPETING INTEREST STATEMENT 
The authors declare that they have no competing financial interests. 
 
FIGURE LEGENDS 
Figure 1 Absorption and circular dichroism (CD) spectroscopy of the metal swap between 
soluble Aβ1−40–Cu(II) and Zn7MT–3. (a) Absorption spectra of Aβ1−40 (black), Aβ1−40–Cu(II) 
(red), Zn7MT–3 (blue), the arithmetic sum of the Aβ1−40–Cu(II) and Zn7MT–3 spectra (cyan) and 
the experimentally obtained spectrum upon the reaction of Aβ1−40–Cu(II) with 0.2 mol equivalent 
of Zn7MT–3 (purple) in 20 mM Tris–HCl, 100 mM NaCl, pH 7.4. (b) CD spectra of Aβ1−40 
(black), Aβ1−40–Cu(II) (red), Zn7MT–3 (blue), Zn7MT–3 to which 1 mol equivalent of free Cu2+ 
was added (cyan), and Aβ1−40–Cu(II) upon the reaction with 1 mol equivalent of Zn7MT–3 
(purple) in 20 mM Tris–HCl, 100 mM, NaCl, pH 7.4. (c) The characteristic Cu(I) luminescence 
spectrum of Cu(I)4Zn4MT–316 obtained upon the reaction of Aβ1−40–Cu(II) with 0.2 mol 
equivalent of Zn7MT–3 (purple). As a control, the luminescence of Aβ1−40–Cu(II) (red) and 
Zn7MT–3 (blue) (both overlaid) are also presented (excitation at 300 nm, at 77 K). Insets: 
Emission lifetimes of both emissive bands in Cu(I)4Zn4MT–3 obtained from the decay fits of the 
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emissive bands at 425 nm (upper panel) and at 565 nm (lower panel). The luminescence bands 
decayed according to a single exponential function. (d) EPR spectrum of Aβ1−40–Cu(II) in 20 mM 
Hepes–NaOH, 100 mM NaCl, pH 7.4, at 80 K. 
 
Figure 2  Metal swap between insoluble aggregated Aβ1−40–Cu(II) and Zn7MT–3. (a) Left panel 
– Copper and zinc content in aggregated (A) and supernatant (S) fractions of Aβ1−40–Cu(II) in the 
absence of Zn7MT–3. Right panel – The same experiment upon the addition of 1 mol equivalent 
of Zn7MT–3. Metal contents of aggregated Aβ1−40 in both panels are normalized to the total 
Aβ1−40 concentration, while the value in the supernatant upon the treatment with Zn7MT–3 is 
presented as a deviation from a total content of 7 Zn(II) per MT–3 molecule. Accordingly, the 
released Zn(II) from MT–3 (a negative bar) was exchanged with a corresponding amount of 
Cu(II) in the aggregates. (b) The low temperature Cu(I) luminescence spectrum of the supernatant 
upon the addition of 1 mol equivalent of Zn7MT–3 to Aβ1−40–Cu(II) aggregates (excitation at 300 
nm). Insets: Emission lifetimes obtained from the decay fits of the emissive bands at 425 nm 
(upper panel) and at 565 nm (lower panel). The luminescence bands decayed according to a 
single exponential function. 
 
Figure 3 Effect of Zn7MT–3 on the nature of aggregated Aβ1−40–Cu(II) and on the hydroxyl 
radical production from soluble and aggregated Aβ1−40–Cu(II). (a) SDS–PAGE analyses of 
Aβ1−40–Cu(II) pellets (peptide/metal ratio 1:1) formed in the absence and presence of increasing 
concentrations of Zn7MT–3 between 50 nM and 25 µM. The corresponding amount of freshly 
diluted monomeric Aβ1−40 is presented as a control (b) The ascorbate–driven copper–catalyzed 
hydroxyl radical production by soluble Aβ1−40–Cu(II) (peptide/metal ratio 4:1) in the absence 
(blue) and presence of Zn7MT–3 (cyan) (peptide/protein ratio 4:1). As a control, the hydroxyl 
radical production by 1 µM CuCl2 (black) and by 1 µM CuCl2 upon the reaction with Zn7MT–3 (1 
µM) (red) are also shown. (c) The hydroxyl radical production by Aβ1−40– Cu(II) aggregates in the 
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absence (blue) and presence of 1 mol equivalent of Zn7MT–3 (black). The hydroxyl radical 
production was monitored by fluorescence of the product 7–OH–CCA (λexc = 395 nm; λem = 450 
nm).  
 
Figure 4 Effect of Aβ1−40–Cu(II) and Zn7MT–3 on the survival of SH–SY5Y neuroblastoma 
cells. (a) SH–SY5Y cells viability in the absence (control) and presence of Aβ1−40–Cu(II), and 
upon the co–incubation of Aβ1−40–Cu(II) with 0.5 mol equivalent of Zn7MT–3 (24 h, 37 °C). All 
experiments were performed in the presence of 300 µM ascorbate. Results are the average of 
three experiments following normalization (n = 3). Statistical significance was determined by P < 
0.05 (* = 0.001; ** = 0.007; *** = 0.015). Error bars show s.d.. (b) SH–SY5Y cells viability 
determined by MTT assay in diluted DMEM (1:10) and in the absence of FCS (24 hours, 37 °C). 
The toxic effect of Cu(II) and Aβ1−40–Cu(II) in the presence of 300 µM ascorbate was compared 
with that of Cu(II). The addition of Zn7MT–3 to Aβ1−40–Cu(II) resulted in a metal swap 
(Supplementary Fig. 6). Results are the average of two experiments (n = 2, ± s.d., P values: * = 
0.051; ** = 0.003; *** = 0.004). (c) The Cu(II) EPR and (d) low temperature Cu(I) luminescence 
spectra of the cell culture samples obtained with sole Aβ1−40–Cu(II) (top) and to which 0.5 mol 
equivalent of Zn7MT–3 was added (middle). As a control, the spectra obtained upon the addition 
of corresponding amounts of CuCl2 and Zn7MT–3 to the culture are also presented (bottom).  
 
 
 
 
 
 
 
 24 
 
Figure 1 
 
 
 
 25 
 
Figure 2 
 
 
 
 
 26 
 
 
Figure 3 
 
 
 
 
 27 
 
 
Figure 4 
Metal swap between Zn7metallothionein–3 and amyloid–β–Cu protects 
against amyloid–β toxicity 
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Supplementary Figure 1  
Supplementary Figure 1. The d–d region of absorption spectra of soluble Aβ1−16–Cu(II)  in 
the presence and absence of Zn7MT–3. Absorption spectra of 257 µM Aβ1−16–Cu(II) (red), 
upon the reaction with 0.2 mol equivalent Zn7MT–3 (green), and of Aβ1−16, (black) in 20 mM 
Hepes–NaOH, 100 mM NaCl, pH 7.4. The absence of d–d transitions of Aβ1−16–Cu(II) upon the 
reaction with Zn7MT–3 confirms the metal swap. 
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Supplementary Figure 2 
Supplementary Figure 2. Circular dichroism (CD) spectra confirming the formation of 
Cu(I)4Zn4MT–3 upon the reaction of Zn7MT–3 with Aβ1−40–Cu(II). CD spectra of 25 µM 
Aβ1−40 (black), upon the reaction of 25 µM CuCl2 with 25 µM Zn7MT–3 (cyan), and upon the 
reaction of 25 µM Aβ1−40–Cu(II) with 25 µM Zn7MT–3 (blue) overlaid with the arithmetic sum of 
the cyan and black spectra (red) in 20 mM Tris–HCl, 100 mM, NaCl, pH 7.4. The identity of the 
blue and red spectra confirms the cooperative formation of Cu(I)4Zn4MT–3 in the reaction 
between Aβ1−40–Cu(II) and Zn7MT–3 1. 
 
 
 
 
1. Meloni, G., Faller, P. & Vašák, M. Redox silencing of copper in metal–linked 
neurodegenerative disorders: reaction of Zn7metallothionein–3 with Cu2+ ions. J. Biol. Chem. 
282, 16068–16078 (2007). 
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Supplementary Figure 3 
Supplementary Figure 3. ESI–MS data of the reaction products between Aβ1−28–Cu(II) and 
Zn7MT–3. ESI–MS data showing the formation of Aβ1−28–67Zn(II) upon the reaction of Aβ1−28–
63Cu(II) with 67Zn7MT–3. The samples were prepared using > 95% enriched 67Zn and 63Cu 
isotopes. Observed masses are summarized in the Supplementary Table 1. 
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Supplementary Figure 4 
 
Supplementary Figure 4. Effect of the ROS production on cell viability. SH–SY5Y 
neuroblastoma cells viability was determined by MTT assay after 24 h incubation at 37 °C (cells 
were cultured in DMEM containing fetal calf serum): A) control; B) 40 µM Aβ1−40–Cu(II); C) 40 
µM Aβ1−40–Cu(II) + 20 µM Zn7MT–3; D); 40 µM Aβ1−40–Cu(II) + 20 µM Cu8MT–3; E) 20 µM 
Zn7MT–3; F) 40 µM Aβ1−40–Zn(II); G) 40 µM Aβ1−40; H) 40 µM Cu(II); all experiments were 
carried out in the presence of 300 µM ascorbate. For comparison cell viability in the presence of 
increasing H2O2 concentrations is also shown. H2O2 was used as the source of ROS in the cell 
culture medium. H2O2 concentrations: I) 1 mM; J) 300 µM; K) 100 µM; L) 60 µM; M) 30 µM; 
N) 10 µM; O) 0.1 µM. The studies showed that the cellular toxicity stems from the ROS 
generated by redox cycling of Cu(II) in the presence of ascorbate.   
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Supplementary Figure 5 
 
Supplementary Figure 5. EPR characterization of the Aβ1−40–Cu(II) complex in diluted 
DMEM buffer. EPR spectra of 40 µM Cu(II) (red) and 40 µM Aβ1−40–Cu(II) (blue) in DMEM 
diluted 1:10 with 20 mM Hepes–NaOH, 100 mM NaCl, pH 7.4. As a control the EPR spectrum 
of 40 µM Aβ1−40–Cu(II) (black) in  20 mM Hepes–NaOH, 100 mM NaCl, pH 7.4, is also shown. 
The spectrum of Aβ1−40–Cu(II) in the medium (blue) resembles much more the spectrum of the 
Aβ1−40–Cu(II) (black) than Cu(II) in the medium (red), suggesting that most of the Cu(II) was 
bound to Aβ1−40 in these conditions. This is best seen for the g┴ signal (indicated by an arrow). 
The analyses of EPR spectra indicate that in DMEM diluted 1:10 with 20 mM Hepes–NaOH, 100 
mM NaCl, pH 7.4, the Aβ1−40–Cu(II) complex represents the major species (~70%, see also 
Supplementary Fig. 6).  
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Supplementary Figure 6. Aβ1−40–Cu(II) formation in the diluted DMEM buffer determined 
by ultrafiltration experiments. Distribution of Cu(II) (40 µM) in DMEM diluted 1:10 with 20 
mM Hepes–NaOH, 100 mM NaCl, pH 7.4, in the presence and absence of Aβ1−40 (40 µM). The 
copper concentration was determined by atomic absorption spectroscopy following the sample 
separation on a 3 kDa cut–off membrane. F and S indicate the flow through and the retained 
fractions, respectively. The results are the average of three independent measurements following 
normalization. Error bars show s.d.. The degree of Aβ1−40 retention by 3 kDa ultrafiltration 
membrane (> 90%) was assessed by size-exclusion chromatography.  
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Supplementary Figure 7. Luminescence spectra of Zn7MT–3 upon the reaction with Aβ1−40–
Cu(II) in diluted DMEM buffer. Luminescence spectra of 40 µM Cu(II) (black), 40 µM Aβ1−40–
Cu(II) (green) and upon the addition of 10 µM Zn7MT–3 (blue) in DMEM diluted 1:10 with 20 
mM Hepes–NaOH, 100 mM NaCl, pH 7.4. As a control the luminescence spectrum of 10 µM 
Zn7MT–3 to which 4 mol equivalents of Cu(II) were added (red). The identity of the blue and red 
spectra confirms the formation of Cu(I)4Zn4MT–3. 
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Supplementary Figure 8. ESI–MS characterization of Aβ1-28. ESI–MS spectra of Aβ1-28 in 10 
mM NH4OAc, 50% acetonitrile (pH = 7.5). The calculated mass of the peptide is 3262.5 Da. 
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Supplementary Figure 9. ESI–MS characterization of Aβ1-40. ESI–MS spectra of Aβ1-40 in 10 
mM NH4OAc, 50% MeOH (pH = 7.5). The calculated mass of the peptide is 4329.9 Da. The 
mass peaks designated (*) indicate the Na+ adducts.
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Supplementary Figure 10. ESI–MS characterization of human apoMT-3. ESI–MS spectra of 
apoMT–3 in 0.2% formic acid, 50% acetonitrile (pH = 2). The calculated mass of the protein is 
6926.9 Da. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 12 
Supplementary Table 1  
 
Supplementary Table 1. ESI–MS data summarizing molecular masses of the reaction 
products between Aβ1−28–Cu(II) and Zn7MT–3. The superscripts in the table refer to the ESI–
MS spectra shown in Supplementary Fig. 3. 
 
 
 
 
 
 
 
 
 
Supplementary Table 2 
 
Supplementary Table 2. ESI–MS data summarizing the MT–3 complexes formed upon the 
reaction of Zn7MT–3 with free Cu(II) and Aβ1–28–Cu(II). ESI–MS data confirm the formation 
of Cu(I)4Zn4MT–3 upon the reaction of Zn7MT–3 with Aβ1−28–Cu(II) (all samples contained both 
metals at natural abundance). For comparison the masses of species obtained upon the titration of 
Zn7MT–3 with free Cu(II) are also presented1. 
 
 
 
Species observed Samples 
Zn7MT–3     (Da) Cu(I)4Zn4MT–3    (Da) 
Zn7MT–3 
Zn7MT–3 + Cu(II) 
Aβ1−28–Cu(II) +  Zn7MT–3 
7368.8  
7368.2 
7368.8 
 
7430.4  
7431.0 
 
1. Meloni, G., Faller, P. & Vašák, M. Redox silencing of copper in metal–linked 
neurodegenerative disorders: reaction of Zn7metallothionein–3 with Cu2+ ions. J. 
Biol. Chem. 282, 16068–16078 (2007). 
Species observed Samples 
Aβ1−28 (Da) Aβ1−28–Cu(II)  (Da) Aβ1−28–Zn(II)  (Da) 
Aβ1−28a 
Aβ1−28 + Cu(II)b  
Aβ1−28 + Zn(II)c   
Aβ1−28–Cu(II) +  Zn7MT–3 
(after mixing)d 
Aβ1−28–Cu(II) +  Zn7MT–3 
(approx. 1 min after reaction)e 
3262.4  
3262.4  
3262.4  
 
3262.4 
 
3262.0  
– 
3323.3  
– 
 
3323.0  
 
(3323.1) 
– 
– 
3326.8  
 
 
 
3326.9  
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ESI–Q–TOF MS measurements. Samples were prepared by mixing Aβ1−28–Cu(II) (125 µM) 
with Zn7MT–3 (285 µM) in 10 mM 4–ethylmorpholine buffer, pH 7.2, at stoichiometries of 1:1, 
4:1, and 8:1. Both the presence of isotopic distribution of Cu and Zn together with their closely 
similar atomic masses make the identification of various metalloforms by MS rather difficult. To 
facilitate their detection the samples were prepared using > 95% enriched 63Cu and 67Zn isotopes. 
Upon mixing, the samples were diluted into 50% 10 mM ammonium acetate, 50% methanol (or 
50% acetonitrile), pH 7.5, and immediately analyzed. Mass spectra have been obtained on a 
nano–ESI–MS Q–TOF Ultima API mass sprectrometer (Micromass, UK). 
 
Cell viability assay followed with 5–carboxyfluorescein diacetate, acetoxymethyl ester. 
Human neuroblastoma SH–SY5Y cells were grown in DMEM (Invitrogen) supplemented with 
10% fetal calf serum (Eurobio), L–glutamine (2 mM) and 0.5% gentamycin at 37 °C in 
humidified 5% CO2 air. To assess the effects of Aβ1–40–Cu(II) and Zn7MT–3 on the Aβ1−40 
induced toxicity, cells were exposed to freshly prepared 40 µM Aβ1–40–Cu(II) in the presence of 
20 µM Zn7MT–3 or Cu8MT–3 and 300 µM ascorbate was added. As a control, cells were grown 
in the absence and presence of Aβ1–40–Cu(II). Cell viability was measured in 24–well plates using 
the fluorescence dye 5–CFDA, AM added to the medium. Briefly, cells exposed to cell–permeant 
5–CFDA, which is hydrolyzed by intracellular esterases, produces a green fluorescence when 
exposed to 492 nm light and is used to identify live cells. Cell viability is expressed as the ratio of 
the signal obtained from treated and control cultures without Aβ1–40–Cu(II). The cell viability was 
assessed after 24 h by fluorescence microscopy using a CCD camera. Since the fluorescence dye 
5–CFDA, AM was found sensitive to H2O2, cell viability in the presence of H2O2 was determined 
through the reduction of MTT. In the MTT assay 24–well plates were used. 25 µl of MTT (5 
mg/ml solution in phosphate buffered saline (PBS)) was added to each well (containing 500 µl 
 14 
medium) and incubated for 3 h. Subsequently, 1 ml DMSO was added and the reduced MTT was 
measured by absorption at 570 nm. Similar cell viability experiments were also performed in 
DMEM medium diluted 1:10 with 20 mM Hepes–NaOH, 100 mM NaCl, pH 7.4, and in the 
absence of fetal calf serum.  
 
 
 
